University of Hyderabad in spotlight after LHC bags ‘science Oscar'
At the heart of this international collaboration is the team led by Dr Bhawna Gomber at the Centre for Advanced Studies in Electronics Science and Technology, School of Physics. Her group made significant contributions to the Compact Muon Solenoid experiment, one of the flagship detectors at the LHC.
Explaining CMS's role within the LHC, Dr Bhawna Gomber told TNIE, 'CMS is a general-purpose detector, playing a crucial role in probing both standard model phenomena and physics beyond the Standard Model. In fact, both CMS and its counterpart ATLAS confirmed the discovery of the Higgs boson in 2012.'
She added, 'Our team is involved in both physics analysis—particularly the search for dark matter using proton-proton collision data — and the development of firmware for the calorimeter trigger system, as part of the detector's Phase-2 upgrade.'
The group's work spans cutting-edge domains including data analysis, trigger electronics, and high-energy particle interactions, contributing significantly to the success of the CMS project.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
3 days ago
- Hans India
Hyderabad: City startup achieves global first in regenerative medicine for liver failure
Hyderabad: In a significant achievement for India's biotechnology sector, Tulsi Therapeutics, a startup incubated at ASPIRE-BioNEST at the University of Hyderabad, has announced the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure. The investigational product, Tulsi-28X, is a groundbreaking regenerative therapy derived from Wharton's Jelly mesenchymal stem cells and their native exosomes. It's a combination that has never been tested in any animal model worldwide. Although conceptualised in the United States, the platform was developed in India through three years of intensive research at ASPIRE-BioNEST. The preclinical trial, conducted in collaboration with global experts including Dr. Naga Chalasani (Indiana University, USA) and Dr. Ajay Duseja (PGIMER, Chandigarh), demonstrated 100% of the animals treated with Tulsi-28x showed reversal of liver fibrosis (indicating liver regeneration) resulting in zero deaths, compared to only 14% reversal (p<0.001) and 43% deaths (p<0.0066) in the untreated control group. 'This is a significant milestone for India's biotech industry,' said Dr. Sairam Atluri, Founder & CEO of Tulsi Therapeutics. 'ASPIRE-BioNEST provided a world-class platform that helped us translate our vision into scientific reality. While human trials are the next challenge, this study opens doors to a new class of biologics in liver disease.' Key results were presented at the prestigious AASLD 2024 Liver Conference in San Diego and accepted for publication in the Journal of Regenerative Medicine. Tulsi Therapeutics is recognised as the world's first biotech company developing a dual stem cell–exosome biologic. Tulsi-28X works by secreting regenerative proteins and growth factors, stimulating the repair of diseased liver tissue. 'We are committed to developing world-class yet affordable regenerative solutions,' said Dr. Ravi Bonthala, Chief Scientific Officer, Tulsi Therapeutics. 'Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences (NIMS).' Chronic liver failure remains a serious public health concern in India, contributing to nearly 20% of global liver-related deaths. With transplantation being the only current treatment, Tulsi-28X represents a potential paradigm shift. 'This milestone highlights how India's innovation ecosystem—anchored by institutions like the University of Hyderabad and enabled by BIRAC and incubators like ASPIRE-BioNEST—is capable of delivering breakthrough global biotech products,' said Prof. B.J. Rao, Vice Chancellor, University of Hyderabad. 'It reflects the power of science, policy, and startup synergy.' 'Tulsi Therapeutics' achievement is a proud moment for all of us at ASPIRE-BioNEST,' said Dr. Anil Kondreddy, CEO, ASPIRE-BioNEST. 'It reflects our mission to nurture science-led innovation with real-world impact. Being rooted in the University of Hyderabad gives us the strength of academic excellence, and it's incredibly fulfilling to see this ecosystem support a global-first breakthrough in regenerative medicine. This is precisely the kind of outcome we work to enable.'
Time of India
3 days ago
- Time of India
City startup incubated at UoH develops stem cell treatment for chronic liver failure
Hyderabad: A startup incubated at the University of Hyderabad (UoH) successfully tested a new treatment for chronic liver failure using stem cells. Called Tulsi-28X, the treatment is touted to be the first in the world by the firm to use a special combination of stem cells and natural healing particles called exosomes. These are taken from a part of the umbilical cord known as Wharton's Jelly. Although the concept was born in the US, the entire platform was developed in India by Tulsi Therapeutics after three years of rigorous research at ASPIRE-BioNEST, UoH's biotech incubator. "We have done trials on rats. All animals treated with Tulsi-28X showed reversal of liver fibrosis, indicating liver regeneration, resulting in zero deaths, compared to only 14% reversal and 43% deaths in the untreated control group," Dr Sairam Atluri, founder & CEO of Tulsi Therapeutics, told TOI. The preclinical trial was conducted in collaboration with Indiana University, US, and PGIMER, Chandigarh. He said that this treatment method can be a game-changer as it would give a new lease of life to those with liver failure and waiting for transplantation. "Right now, the only treatment for liver failure is transplant. However, there are not enough donors, the treatment is very expensive, and it comes with various complications. The medicine that we developed can be administered intravenously," added Atluri, and said he moved from the US to India to work on this idea and bring it to life. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The startup has applied to the Central Drugs Standard Control Organisation (CDSCO) for conducting human trials. "We are committed to developing world-class yet affordable regenerative solutions," said Dr Ravi Bonthala, chief scientific officer of the startup. "Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences."
The Hindu
4 days ago
- The Hindu
University of Hyderabad incubated startup announces successful animal trials of stem cell therapy for liver failure
Tulsi Therapeutics, a startup incubated at ASPIRE-BioNEST,University of Hyderabad (UoH), has announced the world's first successful animal trial of a novel stem cell–exosome combination therapy for chronic liver failure. Chronic liver failure remains a serious public health concern in India, contributing to nearly 20% of global liver-related deaths. With transplantation being the only current treatment, investigational product - 'Tulsi-28X' represents a potential paradigm shift. It works by secreting regenerative proteins and growth factors, stimulating the repair of diseased liver tissue. 'We are committed to developing world-class yet affordable regenerative solutions. Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences (NIMS),' said Tulsi Therapeutics chief scientific officer Ravi Bonthala. The preclinical trial, conducted in collaboration with global experts including Indiana University, (USA) Naga Chalasani and PGIMER, (Chandigarh) Ajay Duseja had demonstrated 100% of the animals treated with 'Tulsi-28x' showed reversal of liver fibrosis (indicating liver regeneration) resulting in zero deaths, compared to only 14% reversal (p<0.001) and 43% deaths (p<0.0066) in the untreated control group, according to a press release on Thursday. While conceptualized in the United States, the platform was entirely developed in India through three years of intensive research at ASPIRE-BioNEST. 'This is a significant milestone for India's biotech industry. ASPIRE-BioNEST provided a world-class platform that helped us translate our vision into scientific reality. While human trials are the next challenge, this study opens doors to a new class of biologics in liver disease,' said founder & CEO of Tulsi Therapeutics Sairam Atluri. Key results were presented at the AASLD 2024 Liver Conference in San Diego (US) and accepted for publication in the 'Journal of Regenerative Medicine'.The firm could also be the first biotech company developing dual stem cell–exosome biologic. It is said to be a first-in-class regenerative therapy derived from Wharton's Jelly mesenchymal stem cells and their native exosomes—a combination never before tested in any animal model worldwide. 'This milestone highlights how India's innovation ecosystem—anchored by institutions like the UoH and enabled by BIRAC and incubators like ASPIRE-BioNEST—is capable of delivering breakthrough global biotech products,' said Vice Chancellor B.J. Rao. 'The achievement is a proud moment for all of us at ASPIRE-BioNEST. It reflects our mission to nurture science-led innovation with real-world impact. it's incredibly fulfilling to see this ecosystem support a global-first breakthrough in regenerative medicine,'said CEO of ASPIRE-BioNEST Anil Kondreddy. ASPIRE-BioNEST supported by BIRAC, Department of Biotechnology, mentors early-stage biotech startups through infrastructure and funding access. It has supported more than 75 deep-tech life sciences startups and was recognized as 'Best Emerging Bio-Incubator' by BIRAC in 2021, added the release.
